Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9552W HIGH $4.84
Volume
7.11 K
Value Traded
28.95 K
Short % Float
4.69%
-3.17%Week
-11.57%1 Month
-20.15%3 Month
-12.3%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.30 M
EPS (TTM)
-1.69
P/E Ratio
-
Ent. Value
-109.07 K
Total Shares
4.02 M
Float Shares
2.56 M
Insiders
36.31%
Institutions
3.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DRMA Catalyst Timeline
Dated clinical, regulatory and corporate events for Dermata Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dermata Therapeutics, Inc.
125Total events
2Upcoming
20Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Product LaunchPost-Market
Launch of Tome Foundational Treatment once-weekly mask
skin renewalsource ↗
●Oral PresentationPresentation
Attended Be+Well Beauty and Wellness Show to launch Tome brand
◆Runway Guidance UpdateCorporate
Cash runway guidance: funds expected to support operations into Q2 2026
▲Product LaunchPost-Market
Launch of once-weekly acne kit (OTC) with Spongilla technology
acnesource ↗
▲Patent GrantedIP / Competition
Australian Patent Office grants patent for Spongilla technology combination for acne treatment
acnesource ↗
▼Equity OfferingCorporate
Closed private placement raising $4.1 million upfront with potential additional $8.3 million from warrant exercise
▼Equity OfferingCorporate
Up to $12.4 million private placement priced at-the-market under Nasdaq rules
◆Trial InitiationXYNGARITrial
Initiation of XYNGARI Phase 3 STAR-2 trial expected in second half of 2025
moderate-to-severe acnesource ↗
▲Topline ReadoutXYNGARIClinical Data
XYNGARI Phase 3 STAR-1 trial shows statistically significant difference at week 4
moderate-to-severe acnesource ↗
▲Additional DataXYNGARIClinical Data
XYNGARI Phase 3 STAR-1 additional positive data announced
moderate-to-severe acnesource ↗
▲Primary Endpoint MetXYNGARIClinical Data
XYNGARI achieved statistically significant separation from placebo after 4 weeks
moderate-to-severe acnesource ↗
◆Topline ReadoutXYNGARIClinical Data
Topline results from XYNGARI Phase 3 STAR-1 trial
moderate-to-severe acnesource ↗
▲Primary Endpoint MetXYNGARIClinical Data
XYNGARI Phase 3 STAR-1 trial met all three primary endpoints with statistical significance
moderate-to-severe acnesource ↗
▲Last Patient Last VisitXYNGARITrial
Last patient completes last visit in XYNGARI Phase 3 STAR-1 trial
moderate-to-severe acnesource ↗
◆Topline ReadoutXYNGARIClinical Data
Topline data expected from XYNGARI Phase 3 STAR-1 trial
moderate-to-severe acnesource ↗
▲Primary Endpoint MetXYNGARIClinical Data
XYNGARI STAR-1 met all three primary endpoints
moderate-to-severe acnesource ↗
●Last Patient Last VisitXYNGARITrial
Last patient last visit in XYNGARI Phase 3 STAR-1 trial
moderate-to-severe acnesource ↗
▼Equity OfferingCorporate
Private placement of 2,007,880 shares and warrants at $1.27 per unit
▲Partnership / LicenseCorporate
Dermata and Revance enter clinical trial collaboration agreement for Xyngari with Daxxify
▲Partnership / LicenseDMT410Corporate
Clinical Trial Collaboration Agreement with Revance for DMT410 with DAXXIFY
axillary hyperhidrosissource ↗
◆Topline ReadoutDMT310Clinical Data
Topline results from DMT310 Phase 3 STAR-1 study
moderate-to-severe acnesource ↗
▼IND WithdrawalXYNGARIIND
Withdrew investigational new drug application for XYNGARI
moderate-to-severe acnesource ↗
●Timing GuidanceDMT310Presentation
NDA filing for DMT310 in acne expected approximately 6 months after trial completion
moderate-to-severe acnesource ↗
◆Enrollment CompleteDMT310Trial
Complete enrollment in DMT310 Phase 3 STAR-1 trial
moderate-to-severe acnesource ↗
▲Enrollment CompleteXYNGARITrial
Completed enrollment in XYNGARI Phase 3 STAR-1 trial
moderate-to-severe acnesource ↗
Past FDA Catalysts and PDUFA Decisions
How DRMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-31 | DMT310 | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 90%
Micro Cap(rank 592 of 658)
Percentile Rank
Dermata Therapeutics, Inc. faces pipeline headwinds (22/100), with $363M risk-adjusted pipeline value, led by DMT310 in Acne Vulgaris (Phase 3), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT310 Small moleculeCompletedNCT04106778 | Acne Vulgaris | Phase 3 | COMPLETED | 822 | May 4, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every DRMA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| XYNGARI | acne | Phase 3 | 2025-05-14 | statistically significant results of its three co-primary endpoints at all time pointsRead More | Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinicalRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Scott Kathleen D.Director | Sell | -11 | $1.19 | 06/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DRMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DRMA for Q2 2026. | ||||
DRMA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DRMA ranks across every disease it competes in
Competitive Position is a premium feature
See how DRMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDRMA News
DRMA▲ +5.5%on this news· ran to -18% by day 3
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
Dermata Therapeutics has officially launched the Tome Foundational Treatment, its first product under the Tome skincare brand. This once-weekly treatment aims to improve skin tone and texture, utilizing Bioneedle technology derived from Spongilla lacustris. The product is available for purchase directly from the company's website, either as a one-time purchase or through a subscription model.
Read more →DRMADermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
Dermata Therapeutics has announced that preorders for its Tome Foundational Treatment are now available, with shipping set to begin on August 25, 2026. This product, designed for skin renewal, will retail at $178 and includes a unique application process. The company aims to fill a gap in the skincare market with this innovative offering.
Read more →DRMADermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics has announced a private placement to raise $3.4 million, with the potential for an additional $6.7 million from warrant exercises. The offering includes shares and warrants priced at $1.46 each, with participation from company insiders. Proceeds will be used for general corporate purposes, including the launch of new skincare products. The closing is expected on August 18, 2026, pending customary conditions.
Read more →DRMA▲ +27.8%on this news· ran to +45% by day 1shared move
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Dermata Therapeutics announced a corporate update highlighting its transition to a direct-to-consumer skincare company. The company plans to launch its first product, Tome Foundational Treatment, on August 25, 2026, following a successful presence at the Be+Well Beauty and Wellness Show. Financial results showed a decrease in cash reserves and increased operational costs, but Dermata remains optimistic about future growth and product development.
Read more →DRMA▲ +6.4%on this news
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
Dermata Therapeutics has announced the commercial launch date for its Tome Foundational Treatment, set for August 25, 2026. This marks the company's first direct-to-consumer skincare product, aimed at providing professional-grade solutions at home. The treatment utilizes proprietary Bioneedle technology and is designed to simplify skincare routines while addressing common skin concerns.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Dermata Therapeutics reported financial results for the first quarter of 2026, highlighting a strategic pivot to the direct-to-consumer skincare market with the launch of their Tome Skincare brand. The company raised $2 million in ATM financing and is preparing for the mid-2026 launch of its initial product, the Foundational Treatment. Despite a decrease in total cash and an ongoing net loss, management remains optimistic about their new direction and product strategies aimed at delivering value to consumers and shareholders.
Read more →DRMA▲ +7.5%on this news
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
Dermata Therapeutics announced the acceptance of its Australian patent application for its Bioneedle Delivery System (BDS) used with dermal fillers. This patent, if issued, would enhance Dermata's intellectual property portfolio and potentially revolutionize the delivery of dermal fillers in the aesthetic market. The BDS aims to provide a non-invasive alternative to traditional injections, improving patient comfort and expanding treatment options.
Read more →DRMA▼ -13.9%on this news
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Dermata Therapeutics has announced a strategic pivot towards direct-to-consumer skincare products, launching its brand Tome. The company plans to introduce its Foundational Treatment in mid-2026, supported by a recent $4.125 million financing round. Dermata is also developing a Clearing Treatment for acne, aiming to simplify skincare routines. Despite positive developments, the company has withdrawn its previous drug application for XYNGARI.
Read more →DRMADermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Dermata Therapeutics has appointed Kyra Peckaitis as Vice President of Marketing to lead the launch of its new skincare brand, Tome. Peckaitis, who has a strong background in brand marketing, will oversee the marketing strategy and consumer engagement initiatives. The first products from Tome are expected to hit the market in mid-2026, aiming to combine scientific innovation with compelling storytelling.
Read more →DRMADermata Opens a New Chapter with the Release of Tome Skincare
Dermata Therapeutics has announced the launch of its new skincare line, Tome, aimed at providing effective, all-natural skincare solutions. Set to debut in mid-2026, Tome will focus on addressing skin conditions with scientifically-backed ingredients. The company is shifting its strategy towards direct-to-consumer products, emphasizing simplicity and efficacy in skincare routines.
Read more →DRMA▼ -5.7%on this news
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Dermata Therapeutics has received a patent grant from the Australian Patent Office for its Spongillatechnology, aimed at treating acne. This patent follows a similar grant in the U.S. and supports the upcoming launch of a once-weekly OTC acne treatment system in mid-2026. The company aims to address significant unmet needs in dermatology with this innovative approach.
Read more →DRMA▲ +22.6%on this news
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics has successfully closed a private placement, raising $4.1 million upfront, with potential additional proceeds of $8.3 million from warrants. The offering included shares of common stock and warrants, priced at $2.04 each. The funds will be used for general corporate purposes, including the development of a new OTC acne kit set to launch in 2026.
Read more →DRMA▲ +16.2%on this newsshared move
Dermata Therapeutics Announces up to $12.4 Million Private Placement At-The-Market Under Nasdaq Rules
Dermata Therapeutics has announced a private placement aimed at raising up to $12.4 million. This includes $4.1 million upfront, with an additional $8.3 million contingent upon the exercise of warrants. The proceeds will be used primarily for research and the launch of an over-the-counter acne kit scheduled for mid-2026. Insider participation in this offering suggests confidence in the company's future prospects, though uncertainties remain regarding the exercise of warrants and market conditions.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Dermata Therapeutics announced a strategic pivot focusing on over-the-counter (OTC) skincare solutions, aiming to launch its first product, an acne treatment kit, by mid-2026. This move follows positive results from its XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne, reinforcing the efficacy of its Spongilla technology. The company reported a financial increase with $4.7 million in cash, although it continues to experience operational losses. Dermata is currently developing branding strategies for its new OTC product line while planning to sell directly to consumers and professionals.
Read more →DRMA▲ +5.5%on this news
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Dermata Therapeutics has announced encouraging results from its XYNGARI Phase 3 STAR-1 clinical trial, which successfully met its three co-primary endpoints for treating moderate-to-severe acne. The company reported a gross fundraising of $8.8 million during the first half of 2025, bolstering its financial capacity to support operations through mid-2026. With positive early data indicating effectiveness as soon as four weeks, Dermata is optimistic about the potential benefits of its Spongilla technology in acne treatment.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Dermata Therapeutics reported encouraging results from its XYNGARI Phase 3 STAR-1 trial, meeting all co-primary endpoints for acne treatment. The company also secured $8.8 million in funding and signed a Clinical Trial Collaboration Agreement with Revance Therapeutics to research DMT410. The upcoming second Phase 3 trial for XYNGARI is set to start soon. Overall, Dermata's advancements demonstrate significant progress in its medical skin disease treatment initiatives.
Read more →DRMADermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Dermata Therapeutics announced that its XYNGARI Phase 3 trial yielded statistically significant results in separating from placebo after just four treatments. In particular, patients showed improvement in inflammatory and non-inflammatory lesion counts as early as week 4. The once-weekly topical treatment could position XYNGARI as a competitive option for patients with moderate-to-severe acne. The company plans to use these positive results to support a future new drug application with the FDA.
Read more →DRMA▲ +5.2%on this news
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Dermata Therapeutics announced positive topline results from its Phase 3 trial of XYNGARI™, a once-weekly topical treatment for moderate-to-severe acne. The trial met all primary endpoints, showing significant efficacy compared to placebo. The product demonstrated a favorable safety profile, with minimal adverse events reported. Dermata plans to initiate a second Phase 3 trial in late 2025.
Read more →DRMA▲ +5.2%on this newsshared move
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics has announced the exercise of warrants, resulting in $6.2 million in gross proceeds to support its ongoing research and development efforts. The company's action includes immediate warrant exercises at a reduced price, leading to the issuance of new Series A and B warrants contingent on shareholder approval. The funds raised will be utilized for corporate purposes, including clinical trials for its product candidates. The offering is set to close on March 28, 2025, pending customary conditions.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Dermata Therapeutics has provided a corporate update alongside its year-end 2024 financial results. The company anticipates announcing topline results from its Phase 3 STAR-1 clinical trial for moderate-to-severe acne by the end of March 2025, following the successful enrollment of participants. Additionally, Dermata entered a collaboration agreement with Revance Therapeutics to advance their DMT410 treatment for hyperhidrosis. While the company raised significant funds, it reported a decrease in cash reserves and elevated research expenditures over the past year.
Read more →About Dermata Therapeutics, Inc.
Headquarters3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next DRMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime